Search hospitals > New Jersey > Mount Holly

Virtua Memorial

Claim this profile
Mount Holly, New Jersey 08060
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
124 reported clinical trials
3 medical researchers
Photo of Virtua Memorial in Mount HollyPhoto of Virtua Memorial in Mount HollyPhoto of Virtua Memorial in Mount Holly

Summary

Virtua Memorial is a medical facility located in Mount Holly, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Virtua Memorial is involved with conducting 124 clinical trials across 172 conditions. There are 3 research doctors associated with this hospital, such as James W. Lee, Randolph B. Deger, and Lemuel S. Ariaratnam.

Area of expertise

1Cancer
Global Leader
Virtua Memorial has run 58 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Virtua Memorial has run 27 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at Virtua Memorial

Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Cancer
Oropharyngeal Carcinoma
Lung Adenocarcinoma
ALK Gene Rearrangement
Laryngeal Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Lung Carcinoma
Image of trial facility.

Sotorasib

for Non-Small Cell Lung Cancer

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Virtua Memorial?
Virtua Memorial is a medical facility located in Mount Holly, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Virtua Memorial is involved with conducting 124 clinical trials across 172 conditions. There are 3 research doctors associated with this hospital, such as James W. Lee, Randolph B. Deger, and Lemuel S. Ariaratnam.